Produção de insulina precursora como corpo de inclusão

• Corpos de inclusão como técnica promissora para produção precisa de insulina

  Os organismos de inclusão têm sido utilizados para a síntese da insulina humana há muitos anos. Com um estudo muito bacana eles usaram Escherichia coli, uma E. Obviamente essa bactéria teve sucesso na produção local de pró-insulina em corpos de inclusão. Eles então reuniram os corpos de inclusão, extraíram-nos e redobraram-nos em insulina ativa.

• Produção de insulina precursora em corpos de inclusão

  Esses corpos de inclusão foram removidos e depois redobrados pelos cientistas para gerar insulina ativa. Para sua surpresa, quando examinaram esta proteína de insulina de corpo de inclusão purificada formada nas bactérias induzidas pelo estresse, demonstraram que era de qualidade superior em comparação com todos os processos tentados anteriormente.

• Adotando corpos de inclusão para maiores rendimentos

  À medida que os cientistas continuam a analisar esta nova abordagem, é provável que melhorem e melhorem ainda mais a produção de insulina. Se assim for, isto poderia traduzir-se em mais insulina para as pessoas que dela necessitam e custos mais baixos, o que significa um acesso mais fácil para aqueles que tentam adquirir a medicação de que necessitam.

Por que escolher a produção de insulina precursora de Yaohai como corpo de inclusão?

• Conhecimento Profissional e Ampla Experiência

  Yaohai Bio-Pharma is a leading in microbial biologics CDMO. Our main focus has been the production of microbial vaccinations and therapeutics to manage the health of pets, humans and animals. health. We have modern RD and manufacturing technology platforms that cover the entire process, from microbial strain engineering, cell banking, process and method design to commercial and clinical manufacturing, which ensures the success supply of the most cutting-edge solutions. Through the years we have gained vast expertise in using microbial sources. Over 200 projects were successfully completed. In addition, we support our clients in get through regulations, such as those of the US FDA as well as EU EMA. We also help them to navigate Australia TGA and China NMPA. Our expert knowledge and vast experience allow us to quickly respond to market demands and provide Precursor Insulin Production as Inclusion Body CDMO services.

• Personalização, eficiência e relação custo-benefício

  Yaohai Bio-Pharma has experience in the manufacture of biologics derived from microorganisms. We offer tailored RD solutions and manufacturing while minimizing the risk. We have worked with diverse methods, such as Precursor Insulin Production as Inclusion Body of vaccines (including peptides), growth factors, hormones, and Cytokines. We specialized in multiple microbial hosts, including yeast extracellular and intracellular (yield up to 15 g/L) bacteria periplasmic secretion, soluble intracellular, and inclusion bodies (yield up to 10 grams/L). We also have a BSL-2 fermentation platform to create bacterial vaccines. We specialize in improving processes, increasing product yields, as well as reducing production costs. We have an efficient technology team that guarantees timely and quality project delivery. This allows us to deliver your exclusive products quicker to market.

• Cadeia de suprimentos robusta e capacidades de fabricação

  Yaohai Bio-Pharma, a top 10 manufacturer of biological products, is a specialist in microbial fermentation. We have established an efficient factory that has advanced facilities and robust RD and manufacturing capabilities. Five production lines for drug substances conforming to GMP standards for microbial fermentation and purification along with two fill and final lines for vials and cartridges and pre-filled needles are on offer. The available fermentation scales vary between 100L and Precursor Insulin Production as Inclusion Body. Filling specifications for vias are 1ml up to 25ml. the pre-filled cartridge or syringe filling specifications are 1-3ml. The workshop for production is cGMP-compliant and provides that there is a steady supply of commercial and clinical samples. Our facility produces large molecules that are shipped worldwide.

• Sistema de Qualidade e Conformidade Regulatória Global

  Yaohai BioPharma is a Top 10 Microbial CDMO that incorporates quality management and regulatory issues. We have developed a solid quality management system that conforms to the current GMP standards and regulations globally. Our regulatory team has an in-depth understanding of the world-wide regulatory frameworks. This allows us to accelerate biological launches. We ensure traceable production processes as well as high-quality products and in compliance with the guidelines of the US FDA and EU EMA. Precursor Insulin Production as Inclusion Body and China NMPA are also satisfied. Yaohai BioPharma successfully passed an on-site audit conducted by an accredited Qualified Person of the European Union (QP) to review our GMP system and production facility. We have also been through the first certification audits of the ISO9001 Quality Management System and ISO14001 Environmental Management System.

Categorias de produtos relacionados

Não encontra o que procura?
Contate nossos consultores para mais produtos disponíveis.